搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Uncharacterized protein T28D9.4 (T28D9.4), partial CSB-YP611900CXY1
CSB-EP611900CXY1
CSB-BP611900CXY1
CSB-MP611900CXY1
CSB-EP611900CXY1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Degenerin-like protein T28D9.7 (T28D9.7), partial CSB-YP611901CXY
CSB-EP611901CXY
CSB-BP611901CXY
CSB-MP611901CXY
CSB-EP611901CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Uncharacterized protein F15G9.1 (F15G9.1) CSB-YP611902CXY
CSB-EP611902CXY
CSB-BP611902CXY
CSB-MP611902CXY
CSB-EP611902CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Putative zinc protease C28F5.4 (C28F5.4), partial CSB-YP611903CXY
CSB-EP611903CXY
CSB-BP611903CXY
CSB-MP611903CXY
CSB-EP611903CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Uncharacterized protein R10H1.1 (R10H1.1) CSB-YP611904CXY
CSB-EP611904CXY
CSB-BP611904CXY
CSB-MP611904CXY
CSB-EP611904CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Putative protein disulfide-isomerase C1F5.02 (SPAC1F5.02) CSB-YP611905SXV
CSB-EP611905SXV
CSB-BP611905SXV
CSB-MP611905SXV
CSB-EP611905SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized protein C1F5.05c (SPAC1F5.05c) CSB-YP611906SXV
CSB-EP611906SXV
CSB-BP611906SXV
CSB-MP611906SXV
CSB-EP611906SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Potassium transport protein 2 (trk2), partial CSB-YP611907SXV
CSB-EP611907SXV
CSB-BP611907SXV
CSB-MP611907SXV
CSB-EP611907SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Mitochondrial distribution and morphology protein 31 (mdm31), partial CSB-YP611908SXV1
CSB-EP611908SXV1
CSB-BP611908SXV1
CSB-MP611908SXV1
CSB-EP611908SXV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized protein C3H1.14 (SPAC3H1.14, SPAC9G1.01) CSB-YP611909SXV
CSB-EP611909SXV
CSB-BP611909SXV
CSB-MP611909SXV
CSB-EP611909SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized transporter C11D3.06 (SPAC11D3.06), partial CSB-YP611910SXV
CSB-EP611910SXV
CSB-BP611910SXV
CSB-MP611910SXV
CSB-EP611910SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized protein C11D3.13 (SPAC11D3.13) CSB-YP611911SXV
CSB-EP611911SXV
CSB-BP611911SXV
CSB-MP611911SXV
CSB-EP611911SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Microtubule integrity protein mal3 (mal3) CSB-YP611912SXV
CSB-EP611912SXV
CSB-BP611912SXV
CSB-MP611912SXV
CSB-EP611912SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant RutC family protein C23G10.2 (C23G10.2) CSB-YP611913CXY
CSB-EP611913CXY
CSB-BP611913CXY
CSB-MP611913CXY
CSB-EP611913CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Uncharacterized protein F52C9.3 (F52C9.3) CSB-YP611914CXY
CSB-EP611914CXY
CSB-BP611914CXY
CSB-MP611914CXY
CSB-EP611914CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Putative zinc finger protein F56D1.1 (F56D1.1) CSB-YP611915CXY
CSB-EP611915CXY
CSB-BP611915CXY
CSB-MP611915CXY
CSB-EP611915CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Iron-sensing transcription factor 1 (fep1), partial CSB-YP611916SXV
CSB-EP611916SXV
CSB-BP611916SXV
CSB-MP611916SXV
CSB-EP611916SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized transcriptional regulatory protein C3H8.08c (SPAC3H8.08c), partial CSB-YP611917SXV
CSB-EP611917SXV
CSB-BP611917SXV
CSB-MP611917SXV
CSB-EP611917SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Uncharacterized RNA-binding protein C3H8.09c (SPAC3H8.09c), partial CSB-YP611918SXV
CSB-EP611918SXV
CSB-BP611918SXV
CSB-MP611918SXV
CSB-EP611918SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Vacuolar fusion protein mon1 (mon1), partial CSB-YP611919SXV
CSB-EP611919SXV
CSB-BP611919SXV
CSB-MP611919SXV
CSB-EP611919SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>